What is the XRTX.V share price today?

This page shows the latest available XORTX Therapeutics Inc. (XRTX.V) price with its change against the prior close. Values are delayed or previous-close, not real-time.

Where is XORTX Therapeutics Inc. listed?

XORTX Therapeutics Inc. trades on the TSX Venture Exchange under the symbol XRTX.V, ISIN CA98420Q4051.

How large is XORTX Therapeutics Inc.?

Its market capitalisation is approximately 888.38K CAD, based on the latest available price and share count from our data provider.

TSX Venture Exchange (TSXV) · XRTX.V · ISIN CA98420Q4051

XORTX Therapeutics Inc.

No trading activity has been reported for this listing since August 31, 2026. It may be delisted, halted or inactive.

3.19 CAD

August 31, 2026

XORTX Therapeutics Inc. (XRTX.V) trades on the TSX Venture Exchange and operates in the Biotechnology industry. Its market capitalisation is approximately 888.38K CAD. The company reports around 2 employees. Its ISIN is CA98420Q4051. This page shows the latest available price, the day and 52-week ranges and an interactive chart. Quotes are delayed and are not intended for order execution.

Key facts

Exchange

TSX Venture Exchange (TSXV)

ISIN

CA98420Q4051

Sector

Healthcare

Industry

Biotechnology

Country

Market cap

888.38K CAD

Employees

Previous close

3.19 CAD

Day range

3.19 – 3.20

52-week range

2.42 – 9.85

Volume

880

50-day average

2.91 CAD

200-day average

3.30 CAD

Asset type

Equity

About XORTX Therapeutics Inc.

Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.

Company website

Frequently asked

What is the XRTX.V share price today?: This page shows the latest available XORTX Therapeutics Inc. (XRTX.V) price with its change against the prior close. Values are delayed or previous-close, not real-time.
Where is XORTX Therapeutics Inc. listed?: XORTX Therapeutics Inc. trades on the TSX Venture Exchange under the symbol XRTX.V, ISIN CA98420Q4051.
How large is XORTX Therapeutics Inc.?: Its market capitalisation is approximately 888.38K CAD, based on the latest available price and share count from our data provider.

All XORTX Therapeutics Inc. data comes from exchange and provider feeds for the TSX Venture Exchange and is published for information, not as investment advice.

Real-time quotes are not licensed; prices are delayed or previous close, so they may lag the market by 15 minutes or a full session. Information only, not for trading. Where a figure is not covered by our licensed sources, the page says so rather than showing a substitute.